RxDoctor Payments Data

Hinh Nguyen, MD

Interventional Cardiology · San Antonio, TXNPI 1225139736

Payments from drug & device makers

$119,227in general payments, 2019–2025

Across 683 payments — averaging $174.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$64K
  • Abiomed$30K
  • Inari Medical, Inc.$12K
  • Teleflex LLC$3K
  • Boston Scientific$3K
  • Actelion Pharmaceuticals US, Inc.$912
  • plus $6K from 39 others

What the payments were for

  • Consulting fees$10,55014%
  • Speaking & faculty fees$33,57546%
  • Travel & lodging$9,05912%
  • Food & beverage$20,23728%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,227 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$492,749
Medicare patients
1,336
Services billed
5,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$214,315
BrilintaTicagrelor92$72,069
XareltoRivaroxaban80$67,356
EntrestoSacubitril/Valsartan49$57,155
FarxigaDapagliflozin Propanediol50$46,420
Repatha SureclickEvolocumab35$22,285
Repatha SyringeEvolocumab30$19,339
ClopidogrelClopidogrel Bisulfate544$6,104
Metoprolol Succinate387$5,197
Amiodarone Hcl69$2,342
Atorvastatin Calcium319$2,295
Rosuvastatin Calcium180$2,237
Losartan Potassium230$2,213
Flecainide Acetate31$1,766
Chlorthalidone97$1,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$363$214,315190 claims
AstraZenecaBrilinta, Farxiga$186$118,489142 claims
Johnson & JohnsonXarelto$799$67,35680 claims
NovartisEntresto$835$57,15549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →